BeOne Medicines (ONC) Operating Leases (2019 - 2026)

BeOne Medicines (ONC) has 8 years of Operating Leases data on file, last reported at $49.7 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 9.52% year-over-year to $49.7 million in Q1 2026; TTM through Mar 2026 was $49.7 million, a 9.52% decrease from a year earlier, with the FY2025 full-year figure at $52.9 million, up 19.57% from the prior year.
• Operating Leases for Q1 2026 stood at $49.7 million, down from $52.9 million in the prior quarter.
• Over the last five years, Operating Leases for ONC reached as high as $54.9 million in Q1 2025 and fell as low as $17.7 million in Q1 2024.
• Historically, Operating Leases has averaged $39.7 million across 5 years, with a median of $40.0 million in 2022.
• Across the five-year window, Operating Leases plunged 46.87% in 2022 and surged 209.76% in 2025, its largest moves.
• Year by year, Operating Leases stood at $34.5 million in 2022, then grew by 28.06% to $44.2 million in 2023, then climbed by 0.17% to $44.3 million in 2024, then climbed by 19.57% to $52.9 million in 2025, then decreased by 6.18% to $49.7 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $49.7 million in Q1 2026, $52.9 million in Q4 2025, and $51.4 million in Q3 2025.